Effect of Palmitoylethanolamide on Visual Field Damage Progression in Normal Tension Glaucoma Patients: Results of an Open-Label Six-Month Follow-Up
Controlled trialHumans
- Design
- Controlled trial
- Subjects
- 32 patients with normal tension glaucoma, randomised to palmitoylethanolamide or no treatment
- Dose used in the study
- 300 mg of ultramicronised palmitoylethanolamide twice a day
- Duration
- 6 months
- What was measured
- Eye pressure, visual acuity and visual field indices
What the authors reported
The trial found:
- Eye pressure fell from 14.4 to 11.1 mmHg in the treated group (p < 0.01), and two visual field indices improved compared with baseline: mean deviation moved from −7.65 dB to −4.55 dB (p < 0.001), and pattern standard deviation from 5.21 dB to 3.81 dB (p < 0.02).
- Visual acuity did not change in either group.
- No side effects were recorded.
Limits of this study
Open-label, with no placebo. The comparison group received nothing, so patients and examiners knew who was treated. 32 patients and 6 months. The entry was checked against the abstract only. Funding was not listed.
Source
PubMed 24827384 · doi:10.1089/jmf.2013.0165
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.